Category Archives: Global News Feed

WOBURN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the LD Micro Main Event XV that will be held October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Southern California.

See original here:
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

Revenue on September 30, 2022

Read more here:
Guerbet: Revenue at September 30, 2022

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, informs its shareholders that the Extraordinary General Meeting (AGE) held on October 17, 2022 has followed the recommendations of the Board of Directors, and adopted all the resolutions that the Board was favorable to, i.e. 10 out of the 11 resolutions.

Follow this link:
DEINOVE - Adoption of the resolutions at the Shareholders’ Extraordinary General Meeting on October 17, 2022

Idorsia will publish its financial results for the first nine months of 2022 on October 25, 2022, at 07:00 CEST.

See the rest here:
Invitation to Idorsia's nine-month financial results 2022 webcast and conference call

Call scheduled for Tuesday, November 8?? at 4:30 pm Eastern Time Call scheduled for Tuesday, November 8?? at 4:30 pm Eastern Time

View post:
Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM)

More here:
Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2022 on Thursday, November 3, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

Read more from the original source:
Codexis to Report Third Quarter 2022 Financial Results on November 3

Monthly information regarding the total number of voting rights and

See the original post:
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022

Excerpt from:
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors

EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other fibrotic diseases, today announced that the peer-reviewed journal, Clinical Pharmacology in Drug Development, has published the results of a clinical trial examining the effect of food on the oral bioavailability of rencofilstat, the Company’s lead drug candidate.

More here:
Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat